

January 25, 2026

## Near term headwinds but future bodes well...

**About the stock:** Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms.

- For Q3FY26, Indian formulations business accounted for ~49% of revenues and major therapies include respiratory, anti-infectives, gastro-intestinal among others
- For Q3FY26, Cipla derived ~21% of the revenues from the US followed by 16% from RoW markets, ~11% from Africa and ~3% from APIs.

## Investment Rationale:

- Q3FY26- Weak Numbers impacted by gRevlimid genericization, Lanreotide issue** - Revenues remained flat YoY at ₹6,963 crore, primarily impacted by 1) weak North America business, which declined 22% to ₹1,485 crore and 2) subdued South Africa revenues which grew just 2% to ₹784 crore due to inventory de-stocking. On the positive side, the domestic business recorded a healthy growth of 10% YoY to ₹3,457 crore, while the RoW markets grew 11% YoY to ₹1,145 crore. Emerging Markets & Europe also reported strong growth of 13% YoY increase to ₹929 crore, driven by strong traction in DTM and B2B segments. EBITDA declined 37% YoY to ₹1,895 crore, with EBITDA margins contracting by 1,038 bps to 17.7%, largely due to a 519-bps decline in gross profit margin to 62.8%. PAT declined 57% YoY to ₹675 crore.
- US slowdown transient; launches in the US and India to materialise over the next 6-18 months- Revenues were weak, largely due to US business, which saw lower traction in gRevlimid and supply constraints for Lanreotide following USFDA observations at the CMO site (Pharmathen). In the US, Cipla plans to launch eight new products over the next 6-18 months, comprising four respiratory products (likely gAdvair, gSymbicort and gQvar) and four peptide products (including gVictoza). Management believes these launches should largely offset the revenue gap created by gRevlimid. India business continued its growth trajectory which is likely to be maintained on the back of increasing traction of the GLP-1 brand Yurpeak (tirzepatide), particularly in tier-2/3 cities, along with the recently acquired brands and traction from the base business. South Africa channel destocking is expected to be completed in the coming quarters. However, considering the near-term headwinds, we have trimmed US revenue estimates for FY27 and FY28 which are now pegged at US\$788 million and US\$907 million, respectively. The management has also revised FY26 EBITDA margin guidance downward to ~21% from 23.5-24.5%. We believe the near-term headwinds are transient in nature and expect momentum from H2FY27 onwards as new launches start materialising.

## Rating and Target price

- We roll forward our estimates and continue to maintain our BUY rating with target price is ₹ 1,570 (vs ₹1,745 earlier) based on 22x FY28E EPS of ₹71.3.

## Key Financial Summary

Key Financials (₹ crore)	FY23	FY24	FY25	3 year CAGR (FY23-26E)	FY26E	FY27E	FY28E	2 year CAGR (FY26E-27E)
Revenues	22753.0	25774.1	27547.6	7.5	28285.0	30749.4	34411.3	10.3
EBITDA	5026.9	6291.1	7127.9	5.4	5893.8	6733.7	7959.9	16.2
EBITDA margins (%)	22.1	24.4	25.9		20.8	21.9	23.1	
Adjusted PAT	2929.9	4263.5	5272.5	12.5	4176.5	4662.7	5739.0	17.2
Adj. EPS (₹)	36.4	53.0	65.5		51.9	57.9	71.3	
PE (x)	37.8	25.7	20.1		26.6	22.7	18.4	
EV to EBITDA (x)	20.4	16.0	13.7		16.7	14.0	11.5	
RoNW (%)	12.5	16.0	16.9		12.7	12.9	14.3	
RoCE (%)	16.5	19.9	19.6		14.8	16.7	19.7	

Source: Company, ICICI Direct Research

Cipla


## Particulars

Particular	Amount
Market Capitalisation	₹ 106121 crore
Debt (FY25)	₹ 92 crore
Cash (FY25)	₹ 589 crore
EV	₹ 105624 crore
52 week H/L (₹)	1673/1303
Equity capital	₹ 161.4 crore
Face value	₹ 2

## Shareholding pattern

(in %)	Mar-25	Jun-25	Sep-25	Dec-25
Promoter	29.2	29.2	29.2	29.2
FIs	26.3	25.2	24.5	23.9
DIs	27.9	29.0	30.0	30.5
Others	16.6	16.6	16.3	16.4

## Shareholding pattern



## Key risks

- Slower ramp up in new launches especially in the US
- Issues popping up at the contract manufacturer's end (Lanreotide like cases)

## Research Analyst

Siddhant Khandekar  
siddhant.khandekar@icicisecurities.com

Shubh Mehta  
shubh.mehta@icicisecurities.com

Vedant Nilekar  
vedant.nilekar@icicisecurities.com

## Exhibit 1: Quarterly Summary

(₹ crore)	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	YoY (%)	QoQ (%)
Net Sales	5730.0	5666.0	6269.4	6589.2	6505.7	6082.4	6624.9	6961.2	6961.6	6597.7	6837.0	7447.4	6963.0	0.0	-6.5
Other Operating Income	80.0	73.4	59.5	88.9	98.2	80.9	69.1	89.8	111.4	132.0	120.4	142.0	111.5	0.1	-21.5
Total Operating Income	5810.0	5739.3	6328.9	6678.2	6603.8	6163.2	6693.9	7051.0	7073.0	6729.7	6957.5	7589.4	7074.5	0.0	-6.8
Raw Material Expenses	2004.3	2063.4	2236.8	2313.1	2219.5	2050.1	2192.9	2283.0	2264.1	2189.0	2170.7	2497.6	2632.1	16.3	5.4
Gross Profit	3805.7	3675.9	4092.1	4365.1	4384.3	4113.1	4501.1	4768.0	4808.9	4540.7	4786.8	5091.8	4442.4	-7.6	-12.8
Gross Profit Margins	65.5	64.0	64.7	65.4	66.4	66.7	67.2	67.6	68.0	67.5	68.8	67.1	62.8	-519 bps	-430 bps
Employee Expenses	948.7	964.8	1066.6	1091.1	1068.1	1084.2	1194.2	1207.9	1197.6	1233.1	1312.3	1314.8	1325.0	10.6	0.8
% of revenues	16.3	16.8	16.9	16.3	16.2	17.6	17.8	17.1	16.9	18.3	18.9	17.3	18.7	180 bps	140 bps
Other Expenditure	1449.6	1537.4	1531.6	1540.2	1568.6	1713.0	1591.0	1674.5	1622.4	1770.0	1696.3	1882.3	1862.4	14.8	-1.1
% of revenues	24.9	26.8	24.2	23.1	23.8	27.8	23.8	23.7	22.9	26.3	24.4	24.8	26.3	339 bps	152 bps
Total Expenditure	4402.5	4565.6	4835.0	4944.4	4856.3	4847.4	4978.1	5165.4	5084.1	5192.1	5179.3	5694.7	5819.4	14.5	2.2
EBITDA	1407.5	1173.7	1493.9	1733.8	1747.5	1315.9	1715.8	1885.6	1988.9	1537.6	1778.1	1894.8	1255.1	-36.9	-33.8
EBITDA (%)	24.2	20.5	23.6	26.0	26.5	21.4	25.6	26.7	28.1	22.8	25.6	25.0	17.7	-1038 bps	-722 bps
Interest	31.8	34.4	16.4	25.8	30.1	17.6	18.0	15.4	14.6	14.0	14.1	13.2	14.0	-4.2	6.4
Depreciation	272.1	346.2	239.2	290.0	233.4	288.3	246.7	271.7	279.8	308.7	252.7	297.0	278.4	-0.5	-6.3
Other Income	114.4	134.6	136.3	176.3	184.6	249.3	160.2	190.6	221.6	289.5	258.6	269.0	206.3	-6.9	-23.3
PBT	1218.0	927.8	1374.6	1594.2	1668.6	1259.3	1611.4	1789.1	1916.1	1504.3	1769.9	1853.5	1169.0	-39.0	-36.9
Total Tax	410.0	222.3	378.0	438.4	405.3	324.9	435.1	483.0	332.4	279.3	477.9	500.5	218.6	-34.2	-56.3
PAT before MI	808.0	523.1	996.6	1155.8	1068.5	934.4	1176.3	1306.0	1583.7	1225.0	1292.1	1353.1	674.6	-57.4	-50.1
Minority Interest	6.9	-4.1	2.4	24.5	12.5	-7.2	-2.2	2.5	4.1	-7.7	-6.0	2.2	-1.6	-138.0	-170.5
PAT	800.9	525.7	995.7	1130.9	1055.9	939.0	1177.6	1302.5	1570.5	1221.8	1297.6	1351.2	675.3	-57.0	-50.0
EPS (₹)	9.9	6.5	12.4	14.0	13.1	11.7	14.6	16.2	19.5	15.2	16.1	16.8	8.4		

Source: Company, ICICI Direct Research

## Q3FY26 Results / Conference call highlights

## India Business –

- Chronic mix improved to 62.3% in the IPM.
- In Licensing portfolio in Rx business contributes less than 10%.
- Management believes it has good headroom to grow in trade and branded generics segments.
- Cipla launched Yurpeak during the quarter and is witnessing good traction with material opportunity in tier 2&3 towns.
- During the quarter Cipla launched 8 new products in trade generics.

## US Business –


- US Business had small contribution of Lenalidomide (gRevlimid). Excluding Lenalidomide Cipla recorded a double-digit growth in the US during the quarter.
- Cipla faced supply chain constraints in some of key products and increased competition in new launches.
- Base Business Excluding Lenalidomide delivered a double-digit growth YoY.
- Cipla had market share of 22% for Albitrol during the quarter.
- Production at Cipla's Lanreotide (hormonal drug) contract Manufacturer, Pharmathen's facility in Rodopi, Greece was temporarily paused due to 9 Form 483 USFDA observations. The supply is expected resume in H1FY27. Till the manufacturing restarts the product will remain in limited supply subject to quality clearance of existing stocks.
- Cipla is evaluating alternative sites for production of lanreotide.
- 4 Respiratory (including gAdvair) and 4 peptide (including Liraglutide) products launches are planned in FY27.
- Three of the four respiratory assets are filed from Cipla's US facilities whereas 1 is filed from Cipla Goa facility.
- Cipla is also planning to launch generic Victoza by Q4FY26.
- All Peptide asses filed from CMO's.
- The launch of Abraxane coincided with other player launch also and hence is facing stiff competition, currently Cipla holds mid-single digit market share.
- Two big respiratory and one small launch are within 6 months.
- Remaining one respiratory launch is expected in 6-12 month.
- 1 small peptide launch is planned in 0-6 month.
- Reinspection of Indore facility by USFDA is expected soon.

**Other Business –**

- South Africa business faced weakness primary revenues during this quarter due to in-country channel destocking. The normalization is expected by next quarter.

**Key Highlights –**

- Cipla entered into Agreement to exclusively market and distribute Pfizer's key brands (Corex, Dolonex, Neksium, Dalacin C) in India for an initial period of 5 years. Pfizer will continue to manufacture, source and supply these medicines to Cipla for India.
- Cipla acquired Inzpera Health sciences for total consideration of ~₹110.65 crore (EV of ₹120 crore), adding a differentiated paediatric and wellness portfolio.
- Cipla has launched Afrezza (insulin human) Inhalation Powder in India. Afrezza is a rapid-acting orally inhaled insulin, which offers a needle-free, convenient alternative to injectable insulin therapy.
- R&D investments for the quarter were ₹494 crore at about 7% of the revenues.
- During the quarter the company had one time impact of ₹276 crore from the new labour code implementation.
- Cipla paid one time licence fees of ₹1107.28 crore to Novartis (Switzerland) for perpetual manufacturing and marketing rights of Galvus and Galvus combination brands.
- Gross margins are expected to be between 60-65% ahead. The company has good margins in its global respiratory products.

**Exhibit 2: 2-year forward PE band**

Source: Company, ICICI Direct Research

**Exhibit 3: Top 10 performing brands in India (in ₹ crore)**

Brand	Therapy	RANK	MAT DEC'22	MAT DEC'23	MAT DEC'24	MAT DEC'25	CAGR MAT DEC'22-DEC'25
FORACORT	Respiratory	1	671.5	834.3	897.3	992.6	14%
DUOLIN	Respiratory	2	418.8	485.9	549.2	640.1	15%
BUDECORT	Respiratory	3	362.7	454.1	490.2	529.5	13%
DYTOR	Cardiac	4	221.9	259.0	315.6	400.1	22%
MONTAIR-LC	Anti Infective	5	271.9	284.2	301.3	353.4	9%
ASTHALIN	Anti Infective	6	266.4	283.2	288.8	321.0	6%
IBUGESIC PLUS	Pain Manager	7	182.2	226.2	259.9	290.2	17%
SEROFLO	Respiratory	8	292.3	293.5	312.4	288.5	0%
AEROCORT	Respiratory	9	202.5	214.7	220.2	245.9	7%
URIMAX-D	Urology	10	143.7	162.6	206.8	238.8	18%

Source: Company, ICICI Direct Research

## Financial Tables

Exhibit 4: Profit and loss statement					₹ crore
(Year-end March)	FY25	FY26E	FY27E	FY28E	
<b>Revenues</b>	<b>27,547.6</b>	<b>28,285.0</b>	<b>30,749.4</b>	<b>34,411.3</b>	
Growth (%)	6.9	2.7	8.7	11.9	
Raw Material Expenses	8,929.0	9,866.1	11,062.7	11,956.0	
Gross Profit	18,618.6	18,418.9	19,686.7	22,455.4	
Employee Expenses	4,832.8	5,085.0	5,070.1	5,673.9	
Other Expenditure	6,657.9	7,440.2	7,882.8	8,821.6	
Total Operating Expenditure	20,419.7	22,391.3	24,015.7	26,451.4	
<b>EBITDA</b>	<b>7,127.9</b>	<b>5,893.8</b>	<b>6,733.7</b>	<b>7,959.9</b>	
Growth (%)	13.3	-17.3	14.3	18.2	
Depreciation	1,107.0	1,106.4	1,343.2	1,229.1	
Interest	62.0	55.3	17.8	15.5	
Other Income	861.9	931.3	1,026.0	1,148.2	
PBT	6,820.8	5,387.5	6,398.8	7,863.5	
Total Tax	1,529.8	1,410.2	1,727.7	2,123.1	
PAT before MI	5,291.1	3,977.2	4,671.1	5,740.4	
Minority Interest	-3.3	-6.9	-2.9	-9.9	
<b>Adjusted PAT</b>	<b>5,272.5</b>	<b>4,176.5</b>	<b>4,662.7</b>	<b>5,739.0</b>	
Growth (%)	23.7	-20.8	11.6	23.1	
<b>EPS (Adjusted)</b>	<b>65.5</b>	<b>51.9</b>	<b>57.9</b>	<b>71.3</b>	
Other income as % of Inv+cash	10%	12%	8%	8%	

Source: Company, ICICI Direct Research

Exhibit 5: Cash flow statement					₹ crore
(Year-end March)	FY25	FY26E	FY27E	FY28E	
Profit/(Loss) after taxation	5,152.7	3,972.8	4,662.7	5,739.0	
Add: Depreciation	1,107.0	1,106.4	1,343.2	1,229.1	
(inc)/Dec in Current Assets	-1,124.4	-1,249.4	560.7	-1,390.0	
inc/(Dec) in Current Liabilities	458.9	817.0	418.1	433.2	
Others	-589.2	55.3	17.8	15.5	
<b>CF from Operating activities</b>	<b>5,005.0</b>	<b>4,702.1</b>	<b>7,002.4</b>	<b>6,026.7</b>	
(Purchase)/Sale of Fixed Assets	-1,514.8	-2,922.0	-1,200.0	-1,200.0	
Change In Investment	-2,125.9	875.4	-1,000.0	-1,000.0	
Others	-50.5	-218.9	-71.5	-81.9	
<b>CF from Investing activities</b>	<b>-3,691.1</b>	<b>-2,265.5</b>	<b>-2,271.5</b>	<b>-2,281.9</b>	
Change in Equity	0.1	0.0	0.0	0.0	
Change in Loan	-178.2	2.2	-67.8	0.0	
Dividend & Dividend tax	-1,049.8	-1,191.8	-1,398.8	-1,721.7	
Others	-64.8	-55.3	-17.8	-15.5	
<b>CF from Financing activities</b>	<b>-1,292.8</b>	<b>-1,244.9</b>	<b>-1,484.4</b>	<b>-1,737.2</b>	
Net Cash Flow	76.4	-320.6	3,246.4	2,007.6	
Cash and Cash equ. at beginning	512.3	588.7	762.1	4,008.5	
<b>Cash</b>	<b>588.7</b>	<b>268.1</b>	<b>4,008.5</b>	<b>6,016.1</b>	
<b>Free Cash Flow</b>	<b>3,490.2</b>	<b>1,780.1</b>	<b>5,802.4</b>	<b>4,826.7</b>	

Source: Company, ICICI Direct Research

Exhibit 6: Balance Sheet					₹ crore
(Year-end March)	FY25	FY26E	FY27E	FY28E	
Equity Capital	161.5	161.6	161.6	161.6	
Reserve and Surplus	31,031.9	32,757.4	36,058.5	40,075.8	
Total Shareholders funds	31,193.5	32,919.0	36,220.1	40,237.4	
Total Debt	92.1	94.3	26.4	26.4	
Deferred Tax Liability	53.5	41.7	43.8	46.0	
Long Term Provision	148.7	157.2	165.1	173.3	
MI & Other Liabilities	495.4	731.3	759.6	782.5	
<b>Source of Funds</b>	<b>31,983.2</b>	<b>33,943.4</b>	<b>37,215.0</b>	<b>41,265.6</b>	
Gross Block - Fixed Assets	17,260.2	19,843.7	20,943.7	22,043.7	
Accumulated Depreciation	10,635.3	11,741.7	13,084.9	14,314.0	
Net Block	6,624.9	8,064.7	7,858.8	7,729.7	
Capital WIP	1,566.3	1,904.7	2,004.7	2,104.7	
Fixed Assets	8,191.1	9,969.4	9,863.5	9,834.4	
Investments	8,044.0	7,168.7	8,168.7	9,168.7	
Goodwill on Consolidation	3,270.3	3,451.3	3,451.3	3,451.3	
Long term Loans & Advances	0.0	0.0	0.1	0.1	
Other Non current assets	1,925.9	2,196.3	2,306.1	2,421.4	
Inventory	5,642.1	6,160.1	6,849.8	7,402.9	
Debtors	5,506.4	6,902.3	5,475.9	6,128.0	
Loans and Advances	15.6	18.0	18.9	19.9	
Other Current Assets	3,991.8	3,502.3	3,677.4	3,861.3	
Cash	588.7	762.1	4,008.5	6,016.1	
Bank Balance other than cash	211.2	33.7	33.7	33.7	
Total Current Assets	15,744.6	17,344.8	20,030.6	23,428.2	
Creditors	2,837.5	3,035.1	3,293.8	3,559.8	
Provisions	1,716.6	1,831.0	1,922.5	2,018.6	
Other current liabilities	849.7	1,354.8	1,422.5	1,493.7	
Total Current Liabilities	5,403.8	6,220.8	6,638.9	7,072.1	
Net Current Assets	10,340.8	11,124.0	13,391.7	16,356.1	
<b>Application of Funds</b>	<b>31,983.2</b>	<b>33,943.4</b>	<b>37,215.0</b>	<b>41,265.6</b>	

Source: Company, ICICI Direct Research

Exhibit 7: Key ratios				
(Year-end March)	FY25	FY26E	FY27E	FY28E
<b>Per share data (₹)</b>				
Adjusted EPS	65.5	51.9	57.9	71.3
BV per share	387.4	408.9	449.9	499.8
Cash per Share	7.3	9.5	49.8	74.7
Dividend per share	16.4	14.8	17.4	21.4
<b>Operating Ratios (%)</b>				
Gross Margins	67.6	65.1	64.0	65.3
EBITDA margins	25.9	20.8	21.9	23.1
PAT Margins	19.1	14.8	15.2	16.7
Inventory days	231	228	226	226
Debtor days	73	89	65	65
Creditor days	116	112	109	109
Asset Turnover	0.9	0.9	1.0	1.0
EBITDA convsn rate	70.2	79.8	104.0	75.7
<b>Return Ratios (%)</b>				
RoE	16.9	12.7	12.9	14.3
RoCE	19.6	14.8	16.7	19.7
RoIC	28.3	20.7	28.7	38.0
<b>Valuation Ratios (x)</b>				
P/E	20.1	26.6	22.7	18.4
EV / EBITDA	13.7	16.7	14.0	11.5
EV / Net Sales	3.6	3.5	3.1	2.6
Market Cap / Sales	3.8	3.7	3.4	3.1
Price to Book Value	3.4	3.2	2.9	2.6
<b>Solvency Ratios</b>				
Debt / EBITDA	0.0	0.0	0.0	0.0
Debt / Equity	0.0	0.0	0.0	0.0
Current Ratio	2.8	2.7	2.4	2.5

Source: Company, ICICI Direct Research

## RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,  
ICICI Securities Limited,  
Third Floor, Brillanto House,  
Road No 13, MIDC,  
Andheri (East)  
Mumbai – 400 093  
research@icicidirect.com

## ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA; Shubh Mehta, MBA(Tech), Vedant Nilekar, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

## Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com).

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 **E-mail Address:** [complianceofficer@icicisecurities.com](mailto:complianceofficer@icicisecurities.com)

For any queries or grievances: Mr. Jeetu Jawrani Email address: [headservicequality@icicidirect.com](mailto:headservicequality@icicidirect.com) Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icicidirect.com](http://icicidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report